| Literature DB >> 29665809 |
Nadia A Sam-Agudu1,2, Muktar H Aliyu3,4, Olusegun A Adeyemi5,6, Frank Oronsaye7, Bolanle Oyeledun7, Amaka G Ogidi8, Echezona E Ezeanolue9,10.
Abstract
BACKGROUND: Implementation research (IR) facilitates health systems strengthening and optimal patient outcomes by generating evidence for scale-up of efficacious strategies in context. Thus, difficulties in generating IR evidence, particularly in limited-resource settings with wide disease prevention and treatment gaps, need to be anticipated and addressed. Nigeria is a priority country for the prevention of mother-to-child transmission of HIV (PMTCT). This paper analyses the experiences of four PMTCT IR studies in Nigeria, and proffers solutions to major challenges encountered during implementation. STUDIES INCLUDED ANDEntities:
Keywords: HIV; Health systems research; Implementation research; Implementation science; Nigeria; PMTCT
Mesh:
Year: 2018 PMID: 29665809 PMCID: PMC5905153 DOI: 10.1186/s12961-018-0309-x
Source DB: PubMed Journal: Health Res Policy Syst ISSN: 1478-4505
Fig. 1Geographical scope of the four PMTCT implementation research studies in Nigeria
Profiles of the four PMTCT implementation research studies in Nigeria, 2012–2017
| Profile indicators | Baby Shower | Optimizing PMTCT | MoMent |
|
|---|---|---|---|---|
| Funder | NIH | NIH | WHO/Global Affairs Canada | WHO/Global Affairs Canada |
| Implementation period | 2012–2015 | 2012–2015 | 2012–2017 | 2012–2017 |
| Local PEPFAR implementing partner | Prevention, Education, Treatment, Training and Research-Global Solutions | Friends in Global Health Nigeria | Institute of Human Virology Nigeria | Center for Integrated Health Programs |
| Study design | Two-arm cluster randomised controlled trial | Two-arm cluster randomised controlled trial | Two-arm prospective matched cohort study | Two-arm cluster randomised controlled trial |
| Study setting | Enugu state (south east zone) | Niger state (north central zone) | Federal Capital Territory and Nasarawa states (north central zone) | Benue and Kaduna states (north central, north west zones) |
| Study sites | Catholic/Anglican churches | Primary and secondary healthcare facilities | Primary healthcare facilities | Primary and secondary healthcare facilities |
| Study settings | Rural and urban | Rural | Rural | Rural and urban |
| Number of study sites | 40 (20 per arm) | 12 (6 per arm) | 20 (10 per arm) | 32 (16 per arm) |
| Formative studies | 2 FGDs with pregnant women, male partners, women’s groups and the clergy | 3 FGDs with study participants | 11 FGDs with pregnant and young women, HIV+ MMs and m2m support group members, male partners | 44 FGDs with women including HIV infected pregnant women and their male partners |
| Core interventions | Congregation-based HIV testing for pregnant women | Point-of-care CD4 testing | Structured, supervised peer support | Structured continuous quality improvement intervention and breakthrough collaborative series |
| Control/standard of care | Routine facility-based HIV testing | Routine PMTCT services | Routine PMTCT services including informal peer support | Routine PMTCT services |
| Study participants | Pregnant women of unknown HIV status | HIV+ pregnant women | HIV+ pregnant women | HIV + pregnant women |
| Primary and key secondary outcome measures | Maternal HIV testing during pregnancy | Maternal ART uptake | Infant EID presentation by 2 months of age | Maternal retention at 6 and 12 months postpartum |
| Original sample size | 2700 pregnant women | 372 HIV+ pregnant women | 480 HIV+ pregnant women | 640 HIV+ pregnant women |
| Revised sample size | N/A | N/A | 220 HIV+ pregnant women | 520 HIV+ pregnant women |
| Final enrolment | ||||
| Pregnant women | 3054 | 369 | 497 | 511 |
| HIV-exposed infants | 69 | 380 | 408 | 403 |
| Male partners | 2498 | N/A | N/A | N/A |
| Summarised results-main outcomes | Women in IG 11 times more likely to have had an HIV test | Women in IG 3 times more likely to initiate ART | Infants in IG 4 times more likely to present for timely EID by 2 months of age | No significant difference in maternal retention at 6 months postpartum |
| 90–90–90 relevance | First 90 (testing) | Second 90 (ART uptake) | Third 90 (viral suppression via adherence) | Third 90 (viral suppression, presumed due to retention) |
NIH National Institutes of Health, WHO World Health Organization
FGD focus group discussion, KII key informant interview, m2m mother2mother, TBA traditional birth attendant, HCW healthcare worker
EID early infant diagnosis, MTCT Mother-to-child transmission of HIV, VL viral load, N/A not applicable
IG intervention group, ART anti-retroviral therapy